| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9005215 | Clinical Therapeutics | 2005 | 16 Pages |
Abstract
Bisphosphonate therapy using intermittent schedules with between-dose intervals longer than 1 week is capable of reducing the risk of fracture, improving BMD, and suppressing biochemical markers of bone turnover. Planned and ongoing trials will determine the place of intermittent bisphosphonates in the treatment algorithm for postmenopausal osteoporosis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
MD Miller,